CardioSomaticsCardioSomaticsCardioСоматика2221-71852658-5707Eco-Vector4517510.26442/CS45175ArticlesСтатьиResearch ArticleThe role of calcium antagonists in the treatment of cardiovascular disease: Focus on diltiazemРоль антагонистов кальция в лечении сердечно-сосудистых заболеваний: фокус на дилтиаземBaryshnikovaG. AБарышниковаГалина Анатольевна

д-р мед. наук, проф. каф. семейной медицины ФГБУ УНМЦ Управления делами ПрезидентаРФ

bargalan@mail.ruChorbinskayaS. AЧорбинскаяСветлана Алексеевна

д-р мед. наук, проф., зав. каф. семейной медицины ФГБУ УНМЦ Управления делами Президента РФ

StepanovaI. IСтепановаИрина Ираклиевна

канд. мед. наук, доц. каф. семейной медицины ФГБУ УНМЦ Управления делами Президента РФ

Teaching and Research Medical Center Office of the President of the Russian Federation, MoscowФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, Москва1503201561NO1 (2015)ТОМ 6, №1 (2015)768224092020Copyright ©; 2015, Eco-VectorCopyright ©; 2015, ООО "Эко-Вектор"2015Eco-VectorООО "Эко-Вектор"https://creativecommons.org/licenses/by-nc-sa/4.0https://cardiosomatics.ru/2221-7185/article/view/45175

The article deals with the use of calcium antagonists (CA) with a focus on diltiazem for the treatment of hypertension, angina pectoris, and cardiac arrhythmias, for secondary prevention of coronary heart disease, to evaluate their cardiac, angiography, nephroprotective effect, the ability to prevent the development of left ventricular hypertrophy. The problems of tolerability and safety of CA in short and prolonged action.

В статье рассматриваются вопросы использования антагонистов кальция (АК) с фокусом на дилтиазем для лечения артериальной гипертензии, стенокардии и нарушений ритма сердца, для вторичной профилактики ишемической болезни сердца, оценивается их кардио -, ангио -, нефропротективное действие, способность предупреждать развитие гипертрофии левого желудочка. Обсуждаются проблемы переносимости и безопасности АК короткого и пролонгированного действия.

diltiazemdiltiazem long-acting calcium channel blockersnedigidropiridinovy antagonists of calciumhypertensionangina pectorismyocardial infarctionдилтиаземдилтиазем пролонгированного действияантагонисты кальциянедигидропиридиновые антагонисты кальцияартериальная гипертониястенокардияинфаркт миокардаFleckenstein A, Tritthart H, Fleckenstein B et al. Eineneue Gruppe - kompetitiver Ca++ Antagonisten (Iproveratril, D6000, Prenylamin) mitstarken Hemeffekten auf die elektromekanische Koppelungim Warmbluter - myocard. Pflugers Arch 1969; 307: R25.Grossman E, Messerli F.H. Calcium antagonists. Progress Cardiovascular Dis 2004; 47 (1): 34-57.Hoberg E, Schwarz F, Schoemig A et al. Prevention of restenosis by verapamil. The verapamil Angioplasty Study (VAS). Circulation 1990; 82 (Suppl. 3): 428.Schroeder J.S, Gao S.Z, Alderman E.L et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart - transplant recipients. N Eng J Med 1993; 328 (3): 164-70.Zanchetti A, Rosei E.A, Dal Palu C et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long - term randomized treatment with either verapamil or chlorthalidone on carotid intima - media thickness. J Hypertens 1998; 16: 1667-76.Furberg C.D, Psaty B.M, Meyer J.V. Dose - related increase in mortality in patients with coronary artery disease. Circulation 1995; 92: 1326-31.Psaty B.M, Heckbert S.R, Koepsell T.D et al. The risk of myocardial infarction assocoated with antihypertensive drug therapies. JAMA 1995; 274: 620-5.Рекомендации Минздрава России. Диагностика и лечение хронической ишемической болезни сердца. 2013.Рекомендации РМОАГ/ВНОК по диагностике и лечению артериальной гипертонии (4-й пересмотр), 2010.Kannel W.B, Kannel C, Paffenbarger R.S et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-94.Gillman M, Kannel W, Belanger A et al. Influence of heart rate on mortality among persons with hypertension: The Framingham study. Am Heart J 1993; 125: 1148-54.Pool P.E, Massie B.M, Venkataraman K et al. Diltiazem as monotherapy for systemic hypertension: a multicenter, randomized, placebo - controlled trial. Am J Cardiol 1986; 57 (4): 212-7.Zannad F, Gosse P, Bernard-Fernier M.F, de La Garoullaye A. Antihypertensive efficacy and tolerability of diltiazem and enalapril, alone or in combination. DESG. Diltiazem Enalapril Study Group. Presse Med 1994; 23 (29): 1335-8.Watts R.W, Wing L.M. A placebo - controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-h ambulatory monitoring. Blood Press 1998; 7 (1): 25-30.Abernethy D.R, Montamat S.C. Acute and chronic studies of diltiazem in elderly vs. young hypertensive patients. Am J Cardiol 1987; 60 (17): 1161-201.Materson B.J, Reda D.J, Cushman W.C et al. Single drug therapy for hypertension in men. A comparison of 6 antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-21.Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and b - blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356 (9227): 359-65.Weiss R.J, Bent B. Diltiazem - induced left ventricular mass regression in hypertensive patients. J Clin Hypertens 1987; 3 (2): 135-43.De Rosa M.L, Giordano A, Melfi M et al. Antianginal efficacy over 24 hours and exercise hemodynamic effects once - daily sustained - release 300 mg diltiazem and 240 mg verapamil in stable angina pectoris. Int J Cardiol 1998; 63: 27-35.Deedwania P.C, Pool P.E, Thadani U, Eff J. Effect of morning vs. evening dosing of diltiazem on myocardial ischemia detected by ambulatory electrocardiographic monitoring in chronic stable angina pectoris. Am J Cardiol 1997; 80: 421-5.Stone P.H, Gibson R.S, Glasser S.P et al. ASIS Study group. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Circulation 1990; 82: 1962-72.Deanfield J.E. Amlodipine vs. diltiazem CR in the reduction of the total ischemic burden: the Circadian Anti - Ischemia Program in Europe (CAPE) II trial - clinical rationale and methodology. Cardiovasc Drug Ther 1998; (12 Suppl. 3): 239-42.Frishman W, Charlap S, Kümmel B et al. Diltiazem, nifedipine and their combination in patients with stable angina pectoris: effect on angina, exercise tolerance, and the ambulatory electrocardiographic ST segment. Circulation 1988; 77: 774-86.Nadeau C, Hilton D, Savard D et al. Three - month efficacy and safety of once - daily diltiazem in chronic stable angina pectoris. Am J Cardiol 1995; 75: 555-8.Waters D, Juneau M, Baierd M. Role of diltiazem in the treatment of silent myocardial ischemia. J Cardiovasc Pharmacol 1991; 18 (Suppl. 9): s15-20.Theroux P, Baird M, Juneau M. Effect of diltiazem upon symptomatic and asymptomatic episodes of ST segment depression occurring during daily life and during exercise. Circulation 1991; 84: 15-22.Opie L.H. Calcium antagonists in the management of anginal syndromes. Changing concepts in relation to the role of coronary vasospasm. Progr Cardiovasc Dis 1996; 38: 291-314.Gubel E.J, Hautvast A.M, Gilst van W et al. Randomised, double - blind trial of intravenous diltiazem vs. glyceryl trinitrate for stable angina pectoris. Lancet 1995; 346: 1653-7.Therous P, Taeymans Y, Morissette D et al. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 1985; 5: 717-22.Gibson R.S, Boden W.E, Therous P et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double - blind, randomized, multicenter trial. N Engl J Med 1986; 315: 423-9.Goldstein R.E, Boccuzzi S.J, Cruess D et al. Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late - onset congestive heart failure in post infarction patients with early reduction in ejection fraction. Circulation 1991; 83: 52-60.Boden W.E, Krone R.J, Kleiger R.E. Electrocardiographic subset analysis of diltiazem administration on long - term outcome after acute myocardial infarction. The Multicenter Diltiazem Post - In - farction Trial Research Group. Am J Cardiol 1991; 67 (5): 335-42.Moss A.J, Oakes D, Rubison M et al. Effects of diltiazem on long - term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. The Multicenter Diltiazem Postinfarction Trial Research Group. Am J Cardiol 1991; 68: 429-33.Gibson R.S, Hansen J.F, Messerli F et al. Long - term effects of diltiazem and verapamil on mortality and cardiac events in non-Q- wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem post infarction trial and the second danish verapamil infarction trial studies. Am J Cardiol 2000; 86: 275-9.Gibson R.S, Boden W.E, Theroux P et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double - blind, randomized, multicenter trial. N Engl J Med 1986; 315: 423-9.Boden W.E, Gilst van W.H, Scheldewaert R.G et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo - controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post - Thrombolysis (INTERCEPT). Lancet 2000; 355 (9217): 1751-6.Nayler W.G. Calcium antagonists and the ischemic myocardium. Int J Cardiol 1987; 15: 267-85.Rosing D.R, Kent K.M, Maron B.J, Epstein S.E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation 1979; 60: 1208-13.Bonow R.O, Dilsizian V, Rosing D.R et al. Verapamil - induced im - provement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short - and long - term effects. Circulation 1985; 72: 853-64.Figulla H, Gietzen F, Raiber M et al. DiDi Study Group. Diltiazem improves cardiac function and exercise capacity in patients with dilated cardiomyopathy. Results of the diltiazem in dilated cardiomyopathy trial. Circulation 1996; 94: 346-52.Opie L. Calcium channel antagonists: part III: Use and comparative efficacy in hypertension and supra ventricular arrhythmias. Minor indications. In: L.H Opie ed. Clinical use of calcium channel antagonist drugs. 2nd ed. Boston, Dordrecht, London: Kluwer Acad. Publishers 1990.Roth A, Harrison E, Mitani et al. Efficacy and safety medium - and high - dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986; 73: 316-24.Cobbe S.M. Using the right drug. A treatment algorithm for atrial fibrillation. Eur Heart J 1997; 18 (Suppl. C): c33-9.Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ, 2012.Pozet N, Brasier J, Aissa A et al. Pharmacokinetics of diltiazem in severe renal failure. Eur J Clin Pharmacol 1983; 24: 635-8.Pérez-Maraver M, Carrera M.J, Mical T et al. Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment. Diabetes Res Clin Pract 2005; 70 (1): 13-9.Hricik D.E, Levine B.S, Adrogue H.J et al. Evaluation of enalapril/diltiazem ER in hypertensive patients with coexisting renal dysfunction. Enalapril/Diltiazem ER in Hypertensive Renal Disease Group. J Hum Hypertens 1996; 10 (11): 769-74.Triggle D. Sites, mechanism of action, and differentiation of calcium channels antagonists. Am J Hypertens 1991; 4: s422-9.Ginsberg D, Pappas J.E, Rofman B.A et al. Once - daily dosing of sustained - release diltiazem capsules in mild - to - moderate hypertension. J Am Osteopath Assoc 1988; 88 (12): 1489-92.